Source-grounded facts extracted from TREACE MEDICAL CONCEPTS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
TREACE MEDICAL CONCEPTS, INC. reported the first quarter ended March 31, 2026 results: revenue $47.2 million, net income $(18.0) million, EPS $(0.28) per share. Guidance reaffirmed.
“treatment of bunions and related midfoot deformities, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights • Generated revenue of $47.2 million in first quarter 2026 compared to $52.6 million in the same period in 2025. • Reported first quarter 2026 net loss of $(18.0) million and adjusted EBITDA of $(5.5) million in the”
Debt Financings
TREACE MEDICAL CONCEPTS, INC. incurred revolving credit of $30 million with Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL at 3-Month SOFR plus 4.00% maturing 60 month.
“The Revolving Loan Agreement establishes a 60 month revolving loan facility providing $30 million in additional borrowing capacity to the Company.”
Debt Financings
TREACE MEDICAL CONCEPTS, INC. incurred term loan of up to $125 million with SLR Investment Corp. at 1-Month SOFR plus 5.05% maturing 60 month.
“The Term Loan Agreement provides a 60 month term loan facility for up to $125 million in borrowing capacity to the Company over four tranches. At the loan closing, the Company drew $60 million under tranche one.”
John T. Treace was appointed as Chairman of the Board at TREACE MEDICAL CONCEPTS, INC..
“appoint John T. Treace to serve as Chairman of the Board, effective upon the expiration of James T. Treace’s current term at the Company’s 2025 Annual Meeting.”
James T. Treace retired as Director at TREACE MEDICAL CONCEPTS, INC..
“his intent to retire from the Board at the expiration of his current term at the 2025 annual meeting of stockholders”
Earnings Releases
TREACE MEDICAL CONCEPTS, INC. reported the first quarter ended March 31, 2024 results: revenue $51.1 million, net income ($18.7) million, EPS ($0.30) per share. Guidance lowered.
“through its flagship Lapiplasty ® and Adductoplasty ® Procedures, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights • Revenue of $51.1 million in first quarter 2024 increased 21% over same period in 2023 • Gross margin of 80.2% in first quarter 2024 • First quarter 2024 net loss attributable to common stockholders was”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.